Co-Diagnostics Q2 2024 GAAP EPS $(0.25) Beats $(0.34) Estimate, Sales $2.656M Beat $375.000K Estimate
Author: Benzinga Newsdesk | August 08, 2024 04:22pm
Co-Diagnostics (NASDAQ:
CODX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.34) by 26.47 percent. The company reported quarterly sales of $2.656 million which beat the analyst consensus estimate of $375.000 thousand by 608.27 percent. This is a 1.24K percent increase over sales of $197.806 thousand the same period last year.
Posted In: CODX